NASDAQ:PROF Profound Medical (PROF) Stock Price, News & Analysis $5.85 +0.05 (+0.86%) Closing price 04:00 PM EasternExtended Trading$5.84 -0.01 (-0.26%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Profound Medical Stock (NASDAQ:PROF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Profound Medical alerts:Sign Up Key Stats Today's Range$5.66▼$5.9850-Day Range$5.60▼$8.3652-Week Range$4.80▼$8.95Volume156,426 shsAverage Volume150,139 shsMarket Capitalization$213.88 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingModerate Buy Company Overview Profound Medical Corp. is a medical technology company focused on developing and commercializing incisionless therapies for prostate disease. The company’s principal product is the TULSA-PRO system, an MRI-guided, robotic platform designed to deliver precise transurethral ultrasound ablation of prostate tissue. The system combines real-time magnetic resonance imaging, automated treatment planning and temperature monitoring to help physicians target and destroy tissue while seeking to protect structures surrounding the prostate. TULSA-PRO is primarily used for the treatment of localized prostate cancer and other prostate conditions, including benign prostatic hyperplasia. The platform is intended to provide a minimally invasive alternative to certain surgical or radiation-based procedures. Profound Medical has obtained regulatory clearances and approvals for TULSA-PRO in the United States, Canada and other international markets, and the company markets the system through hospitals, clinics and physician networks in North America and selected markets internationally. Profound Medical is headquartered in Toronto, Canada. The company was founded to advance image-guided therapeutic technologies and has focused its commercial efforts on expanding adoption of TULSA-PRO and supporting physicians with clinical training and treatment services. Arun Menawat has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Profound Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScorePROF MarketRank™: Profound Medical scored higher than 47% of companies evaluated by MarketBeat, and ranked 584th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingProfound Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialProfound Medical has a consensus price target of $11.50, representing about 96.6% upside from its current price of $5.85.Amount of Analyst CoverageProfound Medical has only been the subject of 2 research reports in the past 90 days.Read more about Profound Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Profound Medical are expected to grow in the coming year, from ($0.81) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Profound Medical is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Profound Medical is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProfound Medical has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Profound Medical's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.37% of the float of Profound Medical has been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 12.33, which indicates bearish sentiment.Change versus previous monthShort interest in Profound Medical has recently decreased by 3.00%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProfound Medical does not currently pay a dividend.Dividend GrowthProfound Medical does not have a long track record of dividend growth. News and Social Media2.4 / 5News SentimentN/A News SentimentProfound Medical has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Profound Medical this week, compared to 2 articles on an average week. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Profound Medical insiders have not sold or bought any company stock.Percentage Held by Insiders1.52% of the stock of Profound Medical is held by insiders.Percentage Held by Institutions47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Profound Medical's insider trading history. Receive PROF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PROF Stock News HeadlinesFinancial Survey: Profound Medical (NASDAQ:PROF) versus Tenon Medical (NASDAQ:TNON)September 30 at 4:29 AM | americanbankingnews.comProfound Medical Stock And 2 Canadian AI Healthcare Stocks To WatchSeptember 6, 2026 | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 1 at 1:00 AM | Stansberry Research (Ad)Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth ConferenceSeptember 3, 2026 | financialpost.comFProfound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth ConferenceSeptember 3, 2026 | globenewswire.comProfound Medical Appoints Richard Fabian PresidentSeptember 2, 2026 | marketscreener.comMProfound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as PresidentSeptember 1, 2026 | financialpost.comFProfound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as PresidentSeptember 1, 2026 | globenewswire.comSee More Headlines PROF Stock Analysis - Frequently Asked Questions How have PROF shares performed this year? Profound Medical's stock was trading at $7.87 at the beginning of 2026. Since then, PROF stock has decreased by 25.7% and is now trading at $5.85. How were Profound Medical's earnings last quarter? Profound Medical (NASDAQ:PROF) announced its earnings results on Thursday, August, 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The firm had revenue of $2.48 million for the quarter, compared to analyst estimates of $4.75 million. Profound Medical had a negative net margin of 171.57% and a negative trailing twelve-month return on equity of 63.03%. Read the conference call transcript. How do I buy shares of Profound Medical? Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Profound Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Docusign (DOCU). Company Calendar Last Earnings8/06/2026Today10/01/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, PROF's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PROF CIK1628808 Webwww.profoundmedical.com Phone(647) 476-1350Fax64-7847-3739Employees162Year Founded2008Price Target and Rating Average Price Target for Profound Medical$11.50 High Price Target$12.00 Low Price Target$11.00 Potential Upside/Downside+96.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.57 million Net Margins-171.57% Pretax Margin-170.37% Return on Equity-63.03% Return on Assets-51.24% Debt Debt-to-Equity RatioN/A Current Ratio6.46 Quick Ratio5.31 Sales & Book Value Annual Sales$16.10 million Price / Sales13.28 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book3.20Miscellaneous Outstanding Shares36,560,000Free Float35,978,000Market Cap$213.88 million OptionableOptionable Beta0.72 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:PROF) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Profound Medical Please log in to your account or sign up in order to add this asset to your watchlist. Share Profound Medical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
